Lantern Pharma Announces Positive LP-184 Phase 1a Results, Advancing Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials

Lantern Pharma reported positive Phase 1a results for LP-184, a biomarker-activated cancer drug-candidate, demonstrating durable disease control in heavily pre-treated advanced cancer patients. The drug met all primary endpoints for safety and tolerability, with a 54% disease control rate at or above therapeutic dose levels. Multiple Phase 1b/2 clinical trials are now planned across cancer indications, supported by FDA designations. The company estimates the aggregate annual market opportunity for LP-184 could exceed $10 billion.